Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.44)
# 314
Out of 5,239 analysts
234
Total ratings
45.5%
Success rate
29.28%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Downgrades: Neutral | $123 → $53 | $52.93 | +0.13% | 7 | Apr 6, 2026 | |
| ADMA ADMA Biologics | Downgrades: Neutral | n/a | $8.41 | - | 10 | Mar 26, 2026 | |
| RNAC Cartesian Therapeutics | Upgrades: Overweight | $16 | $8.70 | +83.91% | 1 | Mar 9, 2026 | |
| QURE uniQure | Upgrades: Neutral | $55 → $9 | $29.10 | -69.07% | 11 | Mar 2, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $153 → $125 | $68.42 | +82.70% | 10 | Feb 17, 2026 | |
| EPRX Eupraxia Pharmaceuticals | Maintains: Overweight | $11 → $19 | $7.61 | +149.67% | 2 | Jan 15, 2026 | |
| DBVT DBV Technologies | Maintains: Overweight | $42 → $48 | $19.94 | +140.72% | 2 | Dec 17, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $15 → $24 | $6.96 | +244.83% | 5 | Dec 8, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $5.70 | +233.33% | 2 | Dec 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $29 → $24 | $11.05 | +117.19% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $38 | $29.37 | +29.38% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $63 | $50.53 | +24.68% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $26.84 | +291.21% | 20 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $75.02 | +57.29% | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $74 | $61.35 | +20.62% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $7.72 | +107.25% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $31.52 | -4.82% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $19.13 | +323.42% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $6.85 | +2.19% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $4.34 | +1,973.73% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $0.25 | +2,745.53% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $32.00 | +109.38% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.16 | +308.65% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.13 | +155.59% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.54 | +333.07% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.68 | +216.90% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $0.81 | +1,620.96% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $0.91 | +1,328.57% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.30 | +1,515.38% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.33 | +351.13% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $0.24 | +8,147.42% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $9.88 | +132.79% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $0.66 | +136,636.55% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $1.61 | +5,179.50% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $8.29 | +2,071.29% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $1.77 | +10,069.49% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.47 | +648.30% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.44 | +4,066.67% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $0.76 | +11,726.54% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $0.59 | +430,669.23% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $0.64 | +472,720.59% | 1 | Jan 9, 2020 |
Soleno Therapeutics
Apr 6, 2026
Downgrades: Neutral
Price Target: $123 → $53
Current: $52.93
Upside: +0.13%
ADMA Biologics
Mar 26, 2026
Downgrades: Neutral
Price Target: n/a
Current: $8.41
Upside: -
Cartesian Therapeutics
Mar 9, 2026
Upgrades: Overweight
Price Target: $16
Current: $8.70
Upside: +83.91%
uniQure
Mar 2, 2026
Upgrades: Neutral
Price Target: $55 → $9
Current: $29.10
Upside: -69.07%
Disc Medicine
Feb 17, 2026
Maintains: Overweight
Price Target: $153 → $125
Current: $68.42
Upside: +82.70%
Eupraxia Pharmaceuticals
Jan 15, 2026
Maintains: Overweight
Price Target: $11 → $19
Current: $7.61
Upside: +149.67%
DBV Technologies
Dec 17, 2025
Maintains: Overweight
Price Target: $42 → $48
Current: $19.94
Upside: +140.72%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Overweight
Price Target: $15 → $24
Current: $6.96
Upside: +244.83%
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $5.70
Upside: +233.33%
Zevra Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $11.05
Upside: +117.19%
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $29.37
Upside: +29.38%
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $50.53
Upside: +24.68%
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $26.84
Upside: +291.21%
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $75.02
Upside: +57.29%
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $61.35
Upside: +20.62%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $7.72
Upside: +107.25%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $31.52
Upside: -4.82%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $19.13
Upside: +323.42%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $6.85
Upside: +2.19%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $4.34
Upside: +1,973.73%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $0.25
Upside: +2,745.53%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $32.00
Upside: +109.38%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $4.16
Upside: +308.65%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $3.13
Upside: +155.59%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.54
Upside: +333.07%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.68
Upside: +216.90%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $0.81
Upside: +1,620.96%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $0.91
Upside: +1,328.57%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.30
Upside: +1,515.38%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.33
Upside: +351.13%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $0.24
Upside: +8,147.42%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $9.88
Upside: +132.79%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $0.66
Upside: +136,636.55%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $1.61
Upside: +5,179.50%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $8.29
Upside: +2,071.29%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $1.77
Upside: +10,069.49%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.47
Upside: +648.30%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.44
Upside: +4,066.67%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $0.76
Upside: +11,726.54%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $0.59
Upside: +430,669.23%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $0.64
Upside: +472,720.59%